|Bid||151.17 x 800|
|Ask||151.36 x 3200|
|Day's Range||150.47 - 151.93|
|52 Week Range||98.23 - 160.25|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||43.24|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||173.00|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...
Masimo , a global leader in innovative noninvasive monitoring technologies, today announced it has closed on a strategic investment with TNI medical AG , a privately held, commercial-stage medical device company headquartered in Würzburg, Germany.
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
EVP & CIO of Masimo Corp (30-Year Financial, Insider Trades) Yongsam Lee (insider trades) sold 8,838 shares of MASI on 08/13/2019 at an average price of $153.5 a share. Continue reading...
In these days of wild market fluctuations, revisiting your portfolio through the dual lenses of circles of competence and comfort can be quite helpful Continue reading...
Masimo announced today that in a study published in the Journal of Clinical Monitoring and Computing, researchers investigated the effects of implementing a hospital-wide fluid and blood administration protocol using two Masimo measurements: noninvasive, continuous hemoglobin and pleth variability index .1 To evaluate the impact of the implementation, they collected data on transfusions and mortality ...
Masimo announced today the CE marking of SpHb®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients . With this clearance, the benefits of SpHb are available for patients of all ages in CE mark countries.
CEO and Chairman of the Board of Masimo Corp (30-Year Financial, Insider Trades) Joe E Kiani (insider trades) sold 21,907 shares of MASI on 08/01/2019 at an average price of $160.01 a share. Continue reading...
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The maker of noninvasive monitoring technologies delivered top- and bottom-line growth despite lower royalty revenue.
CEO and Chairman of the Board of Masimo Corp (30-Year Financial, Insider Trades) Joe E Kiani (insider trades) sold 18,437 shares of MASI on 07/26/2019 at an average price of $160.02 a share. Continue reading...
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo Corporation (NASDAQ:MASI), which is in the medical equipment business, and is based in United States, received...
Masimo announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin m
EVP & CIO of Masimo Corp (30-Year Financial, Insider Trades) Yongsam Lee (insider trades) sold 12,500 shares of MASI on 07/15/2019 at an average price of $151.82 a share. Continue reading...